ReviewClinical pharmacology and therapeutics2026
Navigating the Prescription Drug Information System.
Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Evidence Generation to Decision Making: Completing the Clinical Pharmacology Pathway.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals. Payers need comparative effectiveness data to inform coverage decisions that shape access and resource allocation. However, inadequacies in drug information communication often lead to overestimation of benefits and underestimation of harms. In this White Paper, we explore how information about newly approved drugs is generated, disseminated, and interpreted. We examine the information needs of healthcare professionals, patients, and payers and the influence of regulatory standards on available evidence. Focusing on regulated communication channels, such as prescription drug labeling, medication guides, and clinical trial snapshots, we highlight the foundational role of regulatory agencies in setting evidence standards and legitimizing drug information. We also consider alternative information sources, including pharmaceutical advertising, which coexist with regulated content. Against a backdrop of increasing uncertainty of drug approval evidence, we identify documented principles that regulators can adopt to meet drug information needs. Recommendations for improvements aim to better serve patients, support clinical decision making, and promote ethical healthcare resource allocation. While centered on the US context, the paper draws parallels with the European information landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.